Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | STAT6 | P42226 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9630687 | 1.00 | CYP3A4 (0.44) | CYP3A4ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL9630684 | 1.00 | CYP3A4 (0.44) | CYP3A4ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL21802956 | 1.00 | CYP3A4 (0.44) | CYP3A4ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL23234194 | 0.94 | CYP3A4 (0.43) | CYP3A4ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL3672742 | 0.91 | CYP3A4 (0.41) | CYP3A4ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL3672743 | 0.91 | CYP3A4 (0.41) | CYP3A4ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL3676277 | 0.91 | CYP3A4 (0.48) | CYP3A4ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL3676278 | 0.91 | CYP3A4 (0.48) | CYP3A4ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL17203745 | 0.88 | STAT3 (0.41) | CYP3A4ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL20165805 | 0.88 | STAT3 (0.41) | CYP3A4ALDH1A1LMNATP53NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116807912-A | Use of volatile components to limit or eliminate perception of malodor | 弗门尼舍有限公司 | 2023-09-29 | — | — | CN | claimed |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2023-07-27 | — | — | US | claimed |
| US-20220142158-A1 | ARTHROPOD CONTROL COMPOSITIONS | FIRMENICH SA (CH) | 2022-05-12 | — | — | US | claimed |
| EP-3930460-A1 | ARTHROPOD CONTROL COMPOSITIONS | Firmenich SA (CH) | 2022-01-05 | — | — | EP | claimed |
| WO-2020239954-A1 | ARTHROPOD CONTROL COMPOSITIONS | FIRMENICH SA (CH) | 2020-12-03 | — | — | WO | claimed |
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2020-11-05 | — | — | US | claimed |
| CN-111432851-A | Use of volatile ingredients to limit or eliminate perception of malodour | 弗门尼舍有限公司 | 2020-07-17 | — | — | CN | claimed |
| EP-0302993-B1 | METHYLCYCLODODECATRIEN-1-OLS, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATION | HAARMANN & REIMER GMBH (DE) | 1992-05-06 | — | — | EP | claimed |
| US-4853368-A | Methylcyclododecatri-2,5,9-en-1-ols, a process for their preparation, and their use | HAARMANN & REIMER GMBH (DE) | 1989-08-01 | — | — | US | claimed |
| EP-0302993-A1 | Methylcyclododecatrien-1-ols, method for their production and their application | HAARMANN & REIMER GMBH (DE) | 1989-02-15 | — | — | EP | claimed |
| CN-122028974-A | Ribonucleic acid-based microcapsules | 弗门尼舍有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2026087780-A1 | CORE-SHELL MICROCAPSULES | FIRMENICH SA (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4713129-A1 | ORGANOSILICON-BASED MICROCAPSULES | Firmenich SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4711037-A2 | PERFUME FORMULATION FOR DELIVERY SYSTEM | Firmenich SA (CH) | 2026-03-18 | — | — | EP | disclosed |
| EP-4711438-A2 | PERFUME DELIVERY SYSTEM | Firmenich SA (CH) | 2026-03-18 | — | — | EP | disclosed |
| CN-111432851-A | Use of volatile ingredients to limit or eliminate perception of malodour | 弗门尼舍有限公司 | 2020-07-17 | — | — | CN | disclosed |
| US-20200095518-A1 | PROCESS FOR PREPARING A PERFUMING COMPOSITION | FIRMENICH SA (CH) | 2020-03-26 | — | — | US | disclosed |
| EP-0302993-B1 | METHYLCYCLODODECATRIEN-1-OLS, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATION | HAARMANN & REIMER GMBH (DE) | 1992-05-06 | — | — | EP | disclosed |
| US-4853368-A | Methylcyclododecatri-2,5,9-en-1-ols, a process for their preparation, and their use | HAARMANN & REIMER GMBH (DE) | 1989-08-01 | — | — | US | disclosed |
| EP-0302993-A1 | Methylcyclododecatrien-1-ols, method for their production and their application | HAARMANN & REIMER GMBH (DE) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | CYP3A4 145/4885ALDH1A1 831/4885LMNA 3892/4885 |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | CYP3A4 145/4885ALDH1A1 831/4885LMNA 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.